Pancreatic Cancer Research

ResearcherJohns Hopkins UniversityActive in the last 2 years

Ana De Jesus‐Acosta

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3225-3024; OpenAlex author ID A5031382329, A5160533422. Sources: ClinicalTrials.gov.

Their work

Papers
37 (first author 3, last author 4)
Trials
3 (principal investigator on 3)
Grants
0
Labs led
1
Collaborators
136
Papers, trials and grants by year

2010: 1 trial · 2011: 1 paper, 1 trial · 2012: 2 papers · 2013: 2 papers · 2014: 3 papers · 2015: 2 papers · 2016: 1 paper, 1 trial · 2017: 3 papers · 2018: 2 papers · 2019: 2 papers · 2020: 2 papers · 2021: 4 papers · 2022: 6 papers · 2023: 3 papers · 2024: 1 paper · 2025: 2 papers · 2026: 1 paper

Papers 37

  1. Safety and immunologic impact of neoadjuvant/adjuvant GVAX, cyclophosphamide, pembrolizumab, and anti-CSF1R agent IMC-CS4 in pancreatic adenocarcinoma. Last author DOI 10.3389/fimmu.2026.1715761↗
  2. A Phase II Study of Neoadjuvant GVAX and Cyclophosphamide Combined with Nivolumab and SBRT Followed by Surgery in Borderline Resectable Pancreatic Adenocarcino… Co-author DOI 10.1158/1078-0432.ccr-24-3403↗
  3. New onset diabetes predicts clinical outcomes in patients with pancreatic adenocarcinoma. Last author DOI 10.21037/jgo-24-570↗
  4. Clinical outcomes of liposomal irinotecan in patients with advanced pancreatic cancer previously treated with conventional irinotecan: A meta-analysis of real-… First author DOI 10.1002/cncr.35479↗
  5. A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with r… Co-author DOI 10.1038/s41467-023-39196-9↗
  6. Gemcitabine, Docetaxel, Capecitabine, Cisplatin, Irinotecan as First-line Treatment for Metastatic Pancreatic Cancer. Co-author DOI 10.1158/2767-9764.crc-23-0230↗
  7. Clinical outcomes of liposomal irinotecan in advanced pancreatic adenocarcinoma patients previously treated with conventional irinotecan-based chemotherapy: a … First author DOI 10.3389/fonc.2023.1250136↗
  8. High local failure rates despite high margin-negative resection rates in a cohort of borderline resectable and locally advanced pancreatic cancer patients trea… Co-author DOI 10.1002/cam4.4527↗
  9. The Evolving Paradigm of Germline Testing in Pancreatic Ductal Adenocarcinoma and Implications for Clinical Practice. First author DOI 10.1016/j.path.2022.05.004↗
  10. Cell-free DNA Predicts Prolonged Response to Multi-agent Chemotherapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/2767-9764.crc-22-0343↗
  11. RAD51B Harbors Germline Mutations Associated With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1200/po.21.00404↗
  12. Neoadjuvant Stereotactic Body Radiotherapy After Upfront Chemotherapy Improves Pathologic Outcomes Compared With Chemotherapy Alone for Patients With Borderlin… Co-author DOI 10.1245/s10434-021-11202-8↗
  13. Post-radiation neutrophil-to-lymphocyte ratio is a prognostic marker in patients with localized pancreatic adenocarcinoma treated with anti-PD-1 antibody and s… Co-author DOI 10.3857/roj.2021.01060↗
  14. A Rare Case of Subcutaneous Insulin Resistance Presumed to be due to Paraneoplastic Process in Pancreatic Adenocarcinoma. Co-author DOI 10.1016/j.aace.2021.06.001↗
  15. Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 2013 and 2017. Co-author DOI 10.1016/j.canlet.2020.10.039↗
  16. Survival Outcomes of Adjuvant Chemotherapy Combined With Radiation Versus Chemotherapy Alone After Pancreatectomy for Distal Pancreatic Adenocarcinoma: A Singl… Last author DOI 10.1097/mpa.0000000000001724↗
  17. Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectabl… Co-author DOI 10.1158/1078-0432.ccr-20-2974↗
  18. Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma. Co-author DOI 10.1038/s41416-019-0683-3↗
  19. An exploratory study of metformin with or without rapamycin as maintenance therapy after induction chemotherapy in patients with metastatic pancreatic adenocar… Co-author DOI 10.18632/oncotarget.27586↗
  20. Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer: A Phase 2 Randomized Clinical Trial. Co-author DOI 10.1001/jamaoncol.2019.0684↗
  21. The Significance of Ascites in Patients With Pancreatic Ductal Adenocarcinoma: A Case-Control Study. Last author DOI 10.1097/mpa.0000000000001262↗
  22. Multiplex Proximity Ligation Assay to Identify Potential Prognostic Biomarkers for Improved Survival in Locally Advanced Pancreatic Cancer Patients Treated Wit… Co-author DOI 10.1016/j.ijrobp.2017.10.001↗
  23. Diagnostic intervals and pancreatic ductal adenocarcinoma (PDAC) resectability: a single-center retrospective analysis. Co-author DOI 10.21037/apc.2018.02.01↗
  24. Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer. Co-author DOI 10.1002/cam4.1104↗
  25. The extracellular matrix and focal adhesion kinase signaling regulate cancer stem cell function in pancreatic ductal adenocarcinoma. Co-author DOI 10.1371/journal.pone.0180181↗
  26. Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer. Co-author DOI 10.18632/oncotarget.17237↗
  27. Longer Course of Induction Chemotherapy Followed by Chemoradiation Favors Better Survival Outcomes for Patients With Locally Advanced Pancreatic Cancer. Co-author DOI 10.1097/coc.0000000000000022↗
  28. The prognostic value of stroma in pancreatic cancer in patients receiving adjuvant therapy. Co-author DOI 10.1111/hpb.12334↗
  29. The Role of Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Single-Institution Experience. Co-author DOI 10.1245/s10434-014-4274-5↗
  30. PAK1 mediates pancreatic cancer cell migration and resistance to MET inhibition. Co-author DOI 10.1002/path.4412↗
  31. A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma. Co-author DOI 10.1007/s10637-014-0083-8↗
  32. Baseline hemoglobin-A1c impacts clinical outcomes in patients with pancreatic cancer. Co-author DOI 10.6004/jnccn.2014.0006↗
  33. Resection of borderline resectable pancreatic cancer after neoadjuvant chemoradiation does not depend on improved radiographic appearance of tumor-vessel relat… Co-author DOI 10.1007/s13566-013-0115-6↗
  34. Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer. Co-author DOI 10.1016/j.ijrobp.2013.03.032↗
  35. A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma. Co-author DOI 10.1007/s00280-011-1704-y↗
  36. Molecular determinants of retinoic acid sensitivity in pancreatic cancer. Co-author DOI 10.1158/1078-0432.ccr-11-2165↗
  37. Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Co-author DOI 10.1158/1535-7163.mct-10-0893↗

Trials 3

  1. Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas Principal investigator NCT02451982↗
  2. Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma Principal investigator NCT01431794↗
  3. Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas Principal investigator NCT01088815↗

Closest collaborators

The 25 strongest of 136 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Daniel A. Laheru · 33 shared papers, 1 shared trial, 2010–2026 · strength 3.15
  2. Dung Thi Le · 24 shared papers, 2012–2026 · strength 2.37
  3. Lei Zheng · 22 shared papers, 2012–2026 · strength 2.05
  4. Amol Kumar Narang · 11 shared papers, 2017–2026 · strength 1.32
  5. Jin Peng He · 10 shared papers, 2017–2025 · strength 1.10
  6. Elizabeth M. Jaffee · 10 shared papers, 2014–2026 · strength 1.00
  7. Joseph M. Herman · 13 shared papers, 2013–2022 · strength 0.99
  8. Richard Andrew Burkhart · 7 shared papers, 2018–2026 · strength 0.93
  9. Christopher Lee Wolfgang · 12 shared papers, 2013–2022 · strength 0.80
  10. Amy Hacker‐Prietz · 11 shared papers, 2013–2022 · strength 0.75
  11. Robert A. Anders · 7 shared papers, 2015–2025 · strength 0.72
  12. Christopher L. Wolfgang · 7 shared papers, 2015–2023 · strength 0.68
  13. Hao Wang · 4 shared papers, 2022–2025 · strength 0.63
  14. Nilofer Saba Azad · 7 shared papers, 2016–2023 · strength 0.58
  15. Matthew John Weiss · 7 shared papers, 2015–2022 · strength 0.57
  16. Florencia M. McAllister · 3 shared papers, 2020–2025 · strength 0.54
  17. Valerie Lee · 5 shared papers, 2017–2023 · strength 0.54
  18. Michael Jon Pishvaian · 3 shared papers, 2022–2024 · strength 0.54
  19. Katherine M. Bever · 5 shared papers, 2015–2023 · strength 0.53
  20. Lei Zheng · 4 shared papers, 2018–2024 · strength 0.49
  21. Ralph H. Hruban · 9 shared papers, 2011–2022 · strength 0.47
  22. Chirayu Mohindroo · 2 shared papers, 2022–2025 · strength 0.45
  23. Amol Gupta · 2 shared papers, 2023–2024 · strength 0.43
  24. William R. Burns · 4 shared papers, 2021–2023 · strength 0.43
  25. Anirban Maitra · 6 shared papers, 2011–2022 · strength 0.42

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.